Business Wire

Conrad Hotels & Resorts Unveils Smart Luxury in China’s Fujian Province with Opening of Conrad Xiamen

Del

Conrad Hotels & Resorts, Hilton’s (NYSE: HLT) smart luxury hotel brand, today announced the opening of Conrad Xiamen, on the southwestern coast of Xiamen Island. Owned by Shimao Group and managed by Hilton, Conrad Xiamen is the first Conrad hotel in Fujian province, the sixth in China among a portfolio that includes Conrad Hong Kong, Conrad Sanya Haitang Bay, Conrad Dalian, Conrad Macao, and Conrad Beijing, and joins the larger Hilton portfolio of over 70 hotels in China.

“Conrad Xiamen is an excellent addition to our China portfolio. It underscores our commitment to growing our presence across the top destinations of this market and our confidence in the increasing demand for luxury accommodations from a new generation of smart luxury travelers,” said Bruce McKenzie, senior vice president of operations, Greater China & Mongolia, Hilton.

Conrad Xiamen occupies the 37th to 54th floors of the iconic 300-meter tall Shimao Straits Tower, in the heart of Siming’s Central Business District. Designed to be a shopping, leisure, and business hub, Shimao Straits Tower is a striking sea-facing landmark with a sail-shaped design boasting expansive views of the famous Gulangyu Island. Guests of Conrad Xiamen will enjoy direct access to a shopping mall and a cinema, as well as the prestigious Shapowei dining precinct. Nan Pu tuo Temple and Xiamen University are within walking distance and Conrad Xiamen is also close to major businesses and popular attractions such as Gulangyu Island ferry terminal, Zhongshan Road and Baicheng Beach. Conrad Xiamen is 22 kilometers from Xiamen Gaoqi International Airport.

“We are delighted with the debut of our Conrad Hotel & Resorts brand in Fujian. Conrad Xiamen is a great flagship hotel that epitomizes the luxurious facilities and intuitive service that will provide our guests with inspired experiences and define a new standard for luxury in Xiamen,” said John Vanderslice, global head, Conrad Hotels & Resorts.

Conrad Xiamen has 241 guest rooms and suites with floor-to-ceiling windows that offer breathtaking views. Averaging 60 square meters, the rooms have walk-in wardrobes, large flat screen TVs, Wi-Fi and wired Internet access, Nespresso machines, hydrotherapy rain showers and 400-thread count luxury bed linens. Alternatively, guests can opt for suites and executive rooms with exclusive access to the Executive Lounge on the 54th floor.

Overlooking the city from the 37th floor is a 24-hour Health Club with a full range of cardio and strength training equipment, as well as personal trainers. The heated 25-meter indoor pool offers sea views and guests can also unwind in the Jacuzzi or enjoy personalized treatments at Conrad Spa, which uses only the purest natural products.

With over 2,000 square meters of flexible meeting space and state-of-the-art audiovisual technology, Conrad Xiamen is also an ideal venue for corporate events, social gatherings and weddings. There are eight multifunction meeting rooms that can accommodate up to 210 people and a pillar-less, 760-square meter ballroom that is connected to a sea-facing 380 square meter foyer.

Conrad Xiamen delivers exquisite culinary experiences with its five restaurants and bars. Coast Bar & Grill offers the ultimate sky dining experience, with fresh seafood, grilled specialties and the highest bar in town. Lucheng serves mouth-watering Cantonese and Fujian delicacies, and has eight private rooms that are perfect for small functions. Pier 38 is an all-day dining restaurant with a buffet featuring a vast array of Asian and Western dishes, interactive cooking stations and great sea views. The sophisticated Plush serves High Tea by day and transforms into a vibrant bar in the evenings. Offering fine wines and snacks, it is a great place for socializing and relaxing. And at Parisian patisserie French Kiss, guests can expect fine pastries and Western-style meals.

To ensure that guests enjoy all that the city has to offer by way of culture, art, cuisine and adventure, Conrad Xiamen offers signature Conrad 1/3/5 experiences. Conrad Xiamen also offers the Conrad Concierge app, which enables guests to customize the details of their stay, such as pre-selecting bath amenities, or checking-in while in transit, via a smartphone or tablet.

Conrad Xiamen participates in Hilton HHonors®, the only hotel loyalty program that allows members to earn Points & Miles® on the same stay, with No Blackout Dates on reward stays. Along with HHonors Points, members also enjoy the lowest rates, digital check-in, complimentary internet access, and a booking fee waiver when they book directly through www.conradhotels.com.

Conrad Xiamen is located at No. 186, Yanwuxi Road, Siming District, Xiamen, Fujian Province, 361005, P.R. China. For more information or to make reservations, please call the hotel directly at +86 0592 258 6666, visit the hotel’s website at www.conradhotels.com/xiamen, or follow the hotel on Wechat: Conradxiamen.

Hilton currently operates over 70 hotels in China, recently opening the second Hilton hotel in Xiamen, DoubleTree by Hilton Xiamen-Wuyuan Bay.

For more information about Conrad Hotels & Resorts, please visit http://news.conradhotels.com or follow us at www.facebook.com/ConradHotels, www.instagram.com/ConradHotels, http://twitter.com/ConradHotels.

About Conrad Hotels & Resorts

Conrad Hotels & Resorts is the destination for the new generation of smart luxury travelers for whom life, business, and pleasure seamlessly intersect. Conrad offers its guests an innovative way to Stay Inspired through a curated collections of 1-hour, 3-hour, or 5-hour experiences, available through www.stayinspired.com or through the intuitive Conrad Concierge mobile app. Consisting of 26 properties across five continents, Conrad is part of Hilton, a leading global hospitality company. Connect with Conrad by booking at www.conradhotels.com. Learn more about the brand by visiting http://news.conradhotels.com or following us on Facebook, Instagram, and Twitter.

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company, comprising more than 4,700 managed, franchised, owned and leased hotels and timeshare properties with over 775,000 rooms in 104 countries and territories. For 97 years, Hilton has been dedicated to continuing its tradition of providing exceptional guest experiences. The company's portfolio of 13 world-class global brands includes Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Tru by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonors®. Hilton HHonors members who book directly through preferred Hilton channels have access to benefits including exclusive member rates, free standard Wi-Fi, as well as digital amenities that are available exclusively through the industry-leading Hilton HHonors app, where HHonors members can check-in, choose their room, and access their room using a Digital Key. Visit http://news.hiltonworldwide.com for more information and connect with Hilton on Facebook, Twitter, YouTube, Flickr, LinkedIn and Instagram .

Contact information

Selina Li
Conrad Xiamen
+86 0592 2586666
selena.li@conradhotels.com
or
Audrey Wong
Hilton – Asia Pacific
+65 6833 9763
Audrey.Wong@hilton.com
or
John Walls
Conrad Hotels & Resorts
+1 703 883 5232
john.walls@hilton.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom